IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Don M. Benson, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, Sherif Farag

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Multiple myeloma (MM) patients who receive killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand-matched grafts, suggesting the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect. Expanding on this concept, IPH2101 (1-7F9), an anti-inhibitory KIR mAb, enhances NK-cell function against autologous MM cells by blocking the engagement of inhibitory KIR with cognate ligands, promoting immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. IPH2101 prevents negative regulatory signals by inhibitory KIR, whereas lenalidomide augments NK-cell function and also appears to up-regulate ligands for activating NK-cell receptors on MM cells. Lenalidomide and a murine anti-inhibitory NK-cell receptor Ab mediate in vivo rejection of a lenalidomide-resistant tumor. These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM.

Original languageEnglish
Pages (from-to)6387-6391
Number of pages5
JournalBlood
Volume118
Issue number24
DOIs
StatePublished - Dec 8 2011

Fingerprint

Multiple Myeloma
Natural Killer Cells
Natural Killer Cell Receptors
Ligands
Antibodies
T-cells
Cytotoxicity
Antigen-Antibody Complex
Grafts
Tumors
lenalidomide
IPH 2101
Homologous Transplantation
Up-Regulation
T-Lymphocytes
Transplants
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. / Benson, Don M.; Bakan, Courtney E.; Zhang, Shuhong; Collins, Shauna M.; Liang, Jing; Srivastava, Shivani; Hofmeister, Craig C.; Efebera, Yvonne; Andre, Pascale; Romagne, Francois; Bléry, Mathieu; Bonnafous, Cécile; Zhang, Jianying; Clever, David; Caligiuri, Michael A.; Farag, Sherif.

In: Blood, Vol. 118, No. 24, 08.12.2011, p. 6387-6391.

Research output: Contribution to journalArticle

Benson, DM, Bakan, CE, Zhang, S, Collins, SM, Liang, J, Srivastava, S, Hofmeister, CC, Efebera, Y, Andre, P, Romagne, F, Bléry, M, Bonnafous, C, Zhang, J, Clever, D, Caligiuri, MA & Farag, S 2011, 'IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect', Blood, vol. 118, no. 24, pp. 6387-6391. https://doi.org/10.1182/blood-2011-06-360255
Benson, Don M. ; Bakan, Courtney E. ; Zhang, Shuhong ; Collins, Shauna M. ; Liang, Jing ; Srivastava, Shivani ; Hofmeister, Craig C. ; Efebera, Yvonne ; Andre, Pascale ; Romagne, Francois ; Bléry, Mathieu ; Bonnafous, Cécile ; Zhang, Jianying ; Clever, David ; Caligiuri, Michael A. ; Farag, Sherif. / IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. In: Blood. 2011 ; Vol. 118, No. 24. pp. 6387-6391.
@article{2ee7c3210eb044a48a2a59a68deea973,
title = "IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect",
abstract = "Multiple myeloma (MM) patients who receive killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand-matched grafts, suggesting the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect. Expanding on this concept, IPH2101 (1-7F9), an anti-inhibitory KIR mAb, enhances NK-cell function against autologous MM cells by blocking the engagement of inhibitory KIR with cognate ligands, promoting immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. IPH2101 prevents negative regulatory signals by inhibitory KIR, whereas lenalidomide augments NK-cell function and also appears to up-regulate ligands for activating NK-cell receptors on MM cells. Lenalidomide and a murine anti-inhibitory NK-cell receptor Ab mediate in vivo rejection of a lenalidomide-resistant tumor. These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM.",
author = "Benson, {Don M.} and Bakan, {Courtney E.} and Shuhong Zhang and Collins, {Shauna M.} and Jing Liang and Shivani Srivastava and Hofmeister, {Craig C.} and Yvonne Efebera and Pascale Andre and Francois Romagne and Mathieu Bl{\'e}ry and C{\'e}cile Bonnafous and Jianying Zhang and David Clever and Caligiuri, {Michael A.} and Sherif Farag",
year = "2011",
month = "12",
day = "8",
doi = "10.1182/blood-2011-06-360255",
language = "English",
volume = "118",
pages = "6387--6391",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

AU - Benson, Don M.

AU - Bakan, Courtney E.

AU - Zhang, Shuhong

AU - Collins, Shauna M.

AU - Liang, Jing

AU - Srivastava, Shivani

AU - Hofmeister, Craig C.

AU - Efebera, Yvonne

AU - Andre, Pascale

AU - Romagne, Francois

AU - Bléry, Mathieu

AU - Bonnafous, Cécile

AU - Zhang, Jianying

AU - Clever, David

AU - Caligiuri, Michael A.

AU - Farag, Sherif

PY - 2011/12/8

Y1 - 2011/12/8

N2 - Multiple myeloma (MM) patients who receive killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand-matched grafts, suggesting the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect. Expanding on this concept, IPH2101 (1-7F9), an anti-inhibitory KIR mAb, enhances NK-cell function against autologous MM cells by blocking the engagement of inhibitory KIR with cognate ligands, promoting immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. IPH2101 prevents negative regulatory signals by inhibitory KIR, whereas lenalidomide augments NK-cell function and also appears to up-regulate ligands for activating NK-cell receptors on MM cells. Lenalidomide and a murine anti-inhibitory NK-cell receptor Ab mediate in vivo rejection of a lenalidomide-resistant tumor. These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM.

AB - Multiple myeloma (MM) patients who receive killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand-matched grafts, suggesting the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect. Expanding on this concept, IPH2101 (1-7F9), an anti-inhibitory KIR mAb, enhances NK-cell function against autologous MM cells by blocking the engagement of inhibitory KIR with cognate ligands, promoting immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. IPH2101 prevents negative regulatory signals by inhibitory KIR, whereas lenalidomide augments NK-cell function and also appears to up-regulate ligands for activating NK-cell receptors on MM cells. Lenalidomide and a murine anti-inhibitory NK-cell receptor Ab mediate in vivo rejection of a lenalidomide-resistant tumor. These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM.

UR - http://www.scopus.com/inward/record.url?scp=83455220035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455220035&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-06-360255

DO - 10.1182/blood-2011-06-360255

M3 - Article

C2 - 22031859

AN - SCOPUS:83455220035

VL - 118

SP - 6387

EP - 6391

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -